FEC75

FEC75 is a combination chemotherapy regimen consisting of three drugs: fluorouracil (5-FU), epirubicin, and cyclophosphamide. The "75" refers to the dose of epirubicin at 75 mg/m² per cycle. This regimen is primarily used in the treatment of breast cancer, including both early-stage and metastatic disease. - **Fluorouracil** is an antimetabolite that inhibits DNA synthesis by mimicking nucleotide building blocks[5]. - **Epirubicin** is an anthracycline anti-tumor antibiotic that intercalates into DNA and inhibits topoisomerase II activity, leading to DNA damage[5]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell division[5]. The standard dosing for each cycle includes: - Fluorouracil 500 mg/m² - Epirubicin 75 mg/m² - Cyclophosphamide 500 mg/m² Cycles are typically repeated every 21 days for several cycles depending on clinical protocol[1][3][6]. FEC75 may be used as neoadjuvant or adjuvant therapy in breast cancer and can be followed or preceded by other agents such as paclitaxel and trastuzumab in HER2-positive disease[1][2][6]. Common toxicities include myelosuppression, nausea/vomiting, alopecia, mucositis/stomatitis, cardiotoxicity (from epirubicin), hemorrhagic cystitis (from cyclophosphamide), nail pigmentation changes, and risk of infertility[4][5].

Other names

FEC-75FEC75FEC 75fluorouracil/epirubicin/cyclophosphamide (FEC) 75 regimen